Ming Cheah

Ming Cheah, PhD, joined Pivotal in 2020. Prior to joining Pivotal, Ming was a Group Manager at Roche/Genentech, where he worked in the business development and competitive intelligence groups. At Genentech, Ming had led teams to evaluate external technologies and companies to advise R&D, partnering, and business strategy. Notably, he led scientific diligence to select external clinical collaboration partners and molecules for Roche's novel clinical trial platforms in oncology. Ming also advised clinical development and commercial strategy for multiple drugs in different therapeutic areas, most recently for Tecentriq® (PD-L1 Ab), tiragolumb (TIGIT Ab), and ipatasertib (AKT inhibitor) in oncology, Ocrevus® (CD20 Ab) in multiple sclerosis, and beta amyloid programs in Alzheimer's disease. Prior to Genentech, Ming was a management consultant at McKinsey & Co., with experience advising therapeutics and medtech companies on M&A, business strategy, and operations.

Ming earned his PhD in Immunology from Stanford University School of Medicine under the mentorship of Dr. Irving Weissman, where he discovered and characterized a mechanism for how cancer cells control inflammation in the tumor microenvironment to suppress the immune response. Ming completed his bachelor's and master's degrees in Biology from Yale University, where he published a Nature article and is a co-inventor on a patent on riboswitch-mediated regulation of RNA splicing in fungi.